Blue Yonder Announces Intent To Acquire Doddle To Revolutionize E-Commerce Returns and Redefine Reverse Logistics
Blue Yonder, a leading supply chain solutions provider, today announced the signing of an agreement to acquire Doddle, a leading first and last mile technology business that was co-founded by Tim Robinson and Sir Lloyd Dorfman. Once completed, the deal will allow Blue Yonder’s already robust suite of supply chain management and commerce offerings to expand with full-circle expertise encompassing final mile, returns management and reverse logistics solutions.
With Doddle’s capabilities, Blue Yonder will be able to offer retailers and logistics service providers such as carriers not only a transformed yet simplified experience for their own customers, but also enhanced growth potential as they look to strengthen their businesses and build more sustainable supply chains. In addition, Doddle’s self-service return kiosks and pick-up, drop-off (PUDO) networks offer retail and logistics businesses an efficient, much-needed solution to today’s returns management challenges.
“Doddle has achieved what so few other companies have been able to accomplish: it has cracked the code of first- and last-mile together with omni-channel returns,” said Duncan Angove, CEO, Blue Yonder. “The beauty of Doddle’s solution is that they solve the returns problem end-to-end. From returns initiation, to returns rules, from in-store returns processing to self-service kiosks, right through to warehouse returns handling and back into stock. The proliferation of e-commerce — and, therefore, returns — has placed increased pressure on carriers, muddied the waters of inventory management, and created frustrations for shoppers. Doddle’s capabilities unlock a differentiated, superior customer experience and will help us to further our mission to transform the supply chain.”
While once an afterthought, companies are now recognizing the tremendous importance of robust and optimized delivery and returns offerings, and Doddle’s solutions offer customers a seamless way to reduce costs and inventory waste. In 2022, according to the National Retail Federation, consumers returned over $816 billion worth of products, and some estimates suggest only about 50% of returned products make it back on store shelves. Returns, in particular, are a huge pain point for retailers, carriers and consumers alike and returns management is among the biggest focal points of e-commerce globally in 2023 as the industry becomes increasingly aware of the impact returns can have on customer experience and overall profitability.
With Doddle, Blue Yonder will be the only company with a comprehensive suite from planning and execution to fulfillment and returns to build more sustainable and profitable, end-to-end supply chains. At close, Blue Yonder’s Warehouse Management (WMS), Order Management (OMS), and Transportation Management (TMS) customers, including retailers, logistics service providers, and postal carriers, will be provided with the potential for growth in both scale and cost reduction, with a full-circle logistics experience. Doddle extends Blue Yonder offerings to fully orchestrate the network from customer engagement to stores, fulfillment centers, and logistics, completing the ecosystem needed to support reverse logistics, shipment consolidations, and inventory circularity.
“Today over 900 retailers and logistics providers worldwide work with Doddle to help manage the growing challenges in the first and last mile,” said Tim Robinson, founder and CEO, Doddle. “We knew, however, that in order to find the perfect solution to meet these challenges we needed to integrate our offerings with a strong supply chain planning, orchestration and execution solutions provider. Blue Yonder’s scale and deep expertise is the perfect alliance, and we’re looking forward to helping more businesses tackle these challenges – together.”
This deal is indicative of Blue Yonder's momentum in the supply chain management space and will allow the company to continue to showcase its strength in the retail and logistics industries. The acquisition agreement was signed by Blue Yonder and Doddle on Oct. 11 and the transaction is expected to close in Q4 2023. The intent to acquire Doddle was announced jointly by Angove and Robinson at ICON London, Blue Yonder’s premiere supply chain conference.
About Doddle
Doddle was founded in 2014 by Tim Robinson and Sir Lloyd Dorfman, founder of Travelex. Doddle is the first and last mile technology platform for leading businesses in ecommerce logistics. Our solutions power delivery and returns for brands from Amazon to Australia Post, covering end-to-end returns management, drop-off automation and out-of-home network operation and management. Our goal is to make ecommerce more efficient and sustainable for parcel carriers and retailers, as well as a better experience for consumers. Each solution has been continually innovated upon and updated based on our learnings in the market with partners, so our user journeys are highly optimised and our technology is battle-tested.
Our expertise and technology is trusted by the world’s biggest and best logistics businesses, such as Australia Post, Yamato, Amazon and 100s of retailers worldwide. Headquartered in London, U.K., Doddle also has regional teams in the US, Australia, Europe and Japan.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformations and omni-channel commerce fulfillment. Our end-to-end, cognitive business platform enables retailers, manufacturers and logistics providers to best fulfill customer demand from planning through delivery. With Blue Yonder, you’ll unify your data, supply chain and retail commerce operations to unlock new business opportunities and drive automation, control and orchestration to enable more profitable, sustainable business decisions. Blue Yonder – Fulfill your Potential™blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011291733/en/
Contact information
Blue Yonder Public Relations Contacts:
Marina Renneke, APR, Senior Corporate Communications Director
Tel: +1 480-308-3037, marina.renneke@blueyonder.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
